An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. Caffeic acid phenethyl ester, or CAPE, is a compound isolated from honeybee hive propolis, the resin used by bees to patch up holes in hives...
Prostate Cancer
-
Most Topular Stories
-
Ancient Remedy Slows Prostate Tumor Cell Proliferation
Prostate / Prostate Cancer News From Medical News Today8 May 2012 | 2:00 am -
High PSA Causes
About.com: Prostate Cancer16 May 2012 | 7:09 amWhat are some other causes of an elevated PSA? Thousands of men each year are told that they have a high PSA level after undergoing a routine screening test. The most important and most concerning cause of an elevated PSA is prostate cancer. However, prostate cancer is only one of many potential causes of an elevated PSA. -
What Is The Actual Survival Advantage for Men Who Take Provenge? It’s Longer Than We Thought!
Malecare's Advanced Prostate Cancer3 May 2012 | 7:55 pmUnderstanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since is introduction has attracted nothing but controversy. The first rumblings go all the way back to its initial FDA hearing and just continues all the way to today. I cannot think of many drugs or treatments that can boast of such a rocky history. When… -
Download the Updated Advanced Prostate Cancer Book
Malecare's Advanced Prostate Cancer10 May 2012 | 4:43 pmMalecare’s Advanced Prostate Cancer Book has just had a major update from its first edition. This updated edition can be downloaded for free from the Malecare web page at www.malecare.org. When you get to the page click the box in the upper left of the page that says “ADVANCED PROSTATE CANCER.” Then go to the section that says Advanced Prostate Cancer and fill in your name and email address so we can contact you when there are additional updates. The Advanced Prostate Cancer Book is written for both the newly diagnosed who do not have any understanding of the disease to the… -
Vitamin E in diet protects against many cancers, study suggests
ScienceDaily: Prostate Cancer News23 Apr 2012 | 12:20 pmScientists believe that two forms of vitamin E – gamma and delta-tocopherols – found in soybean, canola and corn oils as well as nuts do prevent colon, lung, breast and prostate cancers while the alpha tocopherols found in vitamin E supplements provide no such protection.
-
MedWorm: Prostate Cancer
-
A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases.
16 May 2012 | 5:07 amAuthors: Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S Abstract Most prostate cancers are treated, although more than 80% remain clinically insignificant and fewer than 3% are fatal. This retrospective study of 240 radical prostatectomy cases with comprehensive follow-up was a search for reliable markers of prostate cancer prognosis evaluable on biopsy specimens to enable minimization of unnecessary treatment, morbidity, and costs. Representative cancer and benign tissue from each prostatectomy specimen was made into tissue microarrays and stained with antibodies targeting 20 gene… -
The dynamics of death in prostate cancer.
16 May 2012 | 5:07 amIn this study, hazard functions were derived for prostate cancer by using survival data on large numbers of patients with prostate cancer with data in the Surveillance, Epidemiology and End Results (SEER) database. The results demonstrate a form of prostate cancer that rapidly evolves to cause death within 5 years, and this form of tumor is only partly identified by routine prognostic variables such as serum prostate-specific antigen (PSA) level, histologic grade, and quantity of tumor. The results also validate the presence of a reservoir of nonfatal prostate cancers that have increased… -
Prostate cancer drug Abiraterone set for approval in England and Wales but not Scotland
16 May 2012 | 3:02 amAbiraterone, marketed as Zytiga, should be given to patients in England and Wales, after a U-turn by the NHS rationing body. It has already been turned down in Scotland. (Source: the Mail online | Health) -
NHS ban on pill to treat prostate cancer is lifted
15 May 2012 | 9:01 pmMEN in the advanced stages of prostate cancer were given hope yesterday when the health -watchdog made a U-turn to approve a drug that can give them precious months of life. (Source: Daily Express - Health) -
Gold Nanocage-CNT Hybrid for Targeted Imaging and Photothermal Destruction of Cancer
15 May 2012 | 7:10 pmChem. Commun., 2012, Accepted ManuscriptDOI: 10.1039/C2CC32313C, CommunicationParesh Ray, Sadia Khan, Zhen Fan, Rajashekar Kanchanapally, Dulal Senapati, Anant Singh, Lule BeqaThis communication reports the design of novel aptamer conjugated gold nanocage decorated SWCNTs hybrid nanomaterial for targeted imaging and selective photothermal destruction of prostate cancer cell.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Chem. Commun. latest articles)
-
MedWorm Query: prostate cancer
-
Women Have a 30% Survival Advantage in Cutaneous Melanoma
12 May 2012 | 4:00 amA new analysis of four large European trials of cutaneous melanoma patients showed a substantial survival advantage for women, most likely explained by underlying biologic differences. (Source: Cancer Network) -
Colon health advocate gives $1M to create medical scholarship for African-Americans
11 May 2012 | 11:06 pmA Mississippi native, Dr. J. Steven Blake has not only adapted to his Mount Airy neighborhood, but also built community around his medical practice. And in his eyes, building community has meant raising awareness of colon cancer and the importance of colon health — a subject which Blake not only calls his job, but his passion. From his Germantown Avenue practice, which houses his Mt. Airy Ambulatory Endoscopy Surgery Center and Blake Gastroenterology Associates, Blake has sought to raise awareness... (Source: bizjournals.com Health Care:Biotechnology headlines) -
Finding a Match and a Mission, to Help Blacks Battle Cancers
11 May 2012 | 10:57 pmSeun Adebiyi launched Nigeria’s national bone-marrow registry, a potential lifesaver for black cancer patients, after experiencing firsthand the difficulty of finding donors for those of African descent. (Source: NYT) -
Preparation and characterization of DNA aptamer based spin column for enrichment and separation of histones
11 May 2012 | 10:05 pmChem. Commun., 2012, Accepted ManuscriptDOI: 10.1039/C2CC32376A, CommunicationKai ZhangCore histones are involved in the regulation of chromatin-templated biological process and have been intimately linked with the development of diseases such as cancer. We have developed a novel approach...The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Chem. Commun. latest articles) -
Simulation of Post-Thyroidectomy Treatment Alternatives for Triiodothyronine or Thyroxine Replacement in Pediatric Thyroid Cancer Patients
11 May 2012 | 9:03 pmThyroid , Vol. 0, No. 0. (Source: Thyroid)
-
MedWorm: Hormone Refractory Prostate Cancer
-
Final NICE guidance does not recommend the use of cabazitaxel for the 2nd line treatment of hormone refractory, metastatic prostate cancer
10 May 2012 | 10:00 pmSource: NICE Area: News Final guidance from the National Institute for Health and Clinical Excellence (NICE) does not recommend cabazitaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. The appraisal committee considered the incremental cost-effectiveness ratio (ICER) of £87,500 per quality-adjusted life year (QALY) gained as the starting point for its decision. The Committee further noted that there remains considerable uncertainty in the robustness of this ICER… -
Quantifying insulin receptor isoform expression in FFPE breast tumors.
29 Apr 2012 | 10:00 pmCONCLUSIONS: The validated, highly sensitive InsR-A and InsR-B qPCR based assays presented here are the first to demonstrate the feasible amplification of InsR isoforms in FFPE tissues. Quantification data generated from this feasibility study indicating InsR-A is more predominant than InsR-B in breast cancer support the use of these assays for further investigation of InsR-A and InsR-B as predictive biomarkers for IGF targeted therapeutics. PMID: 22551578 [PubMed - as supplied by publisher] (Source: Growth Hormone and IGF Research) -
The European Medicines Agency Review of Cabazitaxel (Jevtana(R)) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
2 Apr 2012 | 10:00 pmAuthors: Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F Abstract AbstractOn March 17, 2011 the European Commission issued a marketing authorization valid throughout the European Union for Jevtana® (Sanofi-Aventis, Paris, France) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.The active substance of Jevtana® is cabazitaxel acetone solvate, an antineoplastic agent that acts by disrupting the microtubular network in cells. The recommended dose of cabazitaxel… -
Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway.
1 Apr 2012 | 10:00 pmAuthors: Hsu JL, Ho YF, Li TK, Chen CS, Hsu LC, Guh JH Abstract Combination therapy, which can optimize killing activity to cancers and minimize drug resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs). Rottlerin, a natural polyphenolic component, synergistically increased PC-3 (a HRPC cell line) apoptosis induced by camptothecin (a topoisomerase I inhibitor). Using siRNA technique to knockdown protein kinase C-δ (PKCδ), the data showed that rottlerin-mediated synergistic effect was PKCδ-independent, although rottlerin has been used as a PKCδ inhibitor. -
Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro
1 Apr 2012 | 10:00 pmConclusions: Our findings suggest that the PP depot has the potential to modulate extra-prostatic tumor cells' microenvironment through increased MMPs activity and to promote prostate cancer cell survival and migration. Adipocyte-derived factors likely have a relevant proliferative and motile role. (Source: Journal of Experimental and Clinical Cancer Research)
-
ScienceDaily: Prostate Cancer News
-
Scientists identify prostate cancer stem cells among low-PSA cells
4 May 2012 | 12:59 pmProstate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, scientists have found. -
Gene critical to development and spread of lung cancer identified
24 Apr 2012 | 7:51 pmA single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified. -
Component of pizza seasoning herb oregano kills prostate cancer cells
24 Apr 2012 | 3:22 pmOregano, the common pizza and pasta seasoning herb, has long been known to possess a variety of beneficial health effects, but a new study indicates that an ingredient of this spice could potentially be used to treat prostate cancer, the second leading cause of cancer death in American men. -
Vitamin E in diet protects against many cancers, study suggests
23 Apr 2012 | 12:20 pmScientists believe that two forms of vitamin E – gamma and delta-tocopherols – found in soybean, canola and corn oils as well as nuts do prevent colon, lung, breast and prostate cancers while the alpha tocopherols found in vitamin E supplements provide no such protection. -
Two genetic deletions in human genome linked to the development of aggressive prostate cancer
9 Apr 2012 | 3:42 pmInvestigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer. The findings indicate a man's risk of developing prostate cancer either triples or quadruples, depending on the genetic variant they inherit.
-
Prostate / Prostate Cancer News From Medical News Today
-
In Outcome Of Prostate Cancer Surgery, Higher Hospital Volume More Important Than Surgeon Experience
16 May 2012 | 8:00 amOlder, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital. In such cases, the same research showed the experience level of the surgeon doing the procedure mattered somewhat less than the hospital setting... -
Biomarkers Discovered For Prostate Cancer Detection, Recurrence
15 May 2012 | 6:00 amAlterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found... -
Younger And At-Risk Men Benefit From PSA Screening To Detect Prostate Cancer
8 May 2012 | 5:00 amScreening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal)... -
In Prostate Cancer, Genetic Abnormalities In Benign Or Malignant Tissues Predict Relapse
8 May 2012 | 5:00 amWhile active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge... -
Ancient Remedy Slows Prostate Tumor Cell Proliferation
8 May 2012 | 2:00 amAn over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. Caffeic acid phenethyl ester, or CAPE, is a compound isolated from honeybee hive propolis, the resin used by bees to patch up holes in hives...
-
MedicineNet Prostate Cancer Specialty
-
Can Testosterone Therapy Help Obese Men Lose Weight?
9 May 2012 | 2:00 amTitle: Can Testosterone Therapy Help Obese Men Lose Weight?Category: Health NewsCreated: 5/9/2012 10:05:00 AMLast Editorial Review: 5/9/2012 12:00:00 AM -
CT Scan (Computerized Tomography)
27 Apr 2012 | 2:00 amTitle: CT Scan (Computerized Tomography)Category: Procedures and TestsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/27/2012 12:00:00 AM -
Prostate Cancer Screening Guidelines Often Not Followed: Study
25 Apr 2012 | 2:00 amTitle: Prostate Cancer Screening Guidelines Often Not Followed: StudyCategory: Health NewsCreated: 4/24/2012 6:06:00 PMLast Editorial Review: 4/25/2012 12:00:00 AM -
PSA Test (Prostate Specific Antigen)
23 Apr 2012 | 2:00 amTitle: PSA Test (Prostate Specific Antigen)Category: Procedures and TestsCreated: 11/28/1998 10:45:00 AMLast Editorial Review: 4/23/2012 12:00:00 AM -
Health Highlights: April 18, 2012
19 Apr 2012 | 2:00 amTitle: Health Highlights: April 18, 2012Category: Health NewsCreated: 4/18/2012 2:05:00 PMLast Editorial Review: 4/19/2012 12:00:00 AM
-
Prostate Cancer - Articles - Zimbio
-
Prostate Cancer w/ Bone Metastasis
16 May 2012 | 5:09 amGerald Aptaker, 71. Stage IV Prostate Cancer with multiple bone metastases in bilateral ribs, thoracic spine, sacrum, pelvis and left femur responded dramatically to the Issels Treatment. Within 3 weeks the PSA of 3524 dropped to 639.9, pain minimized, appetite and overall well being improved and energy level went up. Laboratory studies of July 1st, about 1 month after Geralds discharge from the Issels Treatment Center, showed a PSA level of 17.27 and Gerald reported a substantial improvement in his quality of life, with practically no bone pain, no limitations in his range of motion. August… -
Prostate Cancer Awareness Polo Health Golf Shirt by CafePress
16 May 2012 | 4:50 amProstate Cancer Awareness Polo Health Golf Shirt by CafePress Show your support for Prostate Cancer Awareness Health Tee, TShirt, Shirt. About our Golf Shirt: Tee off in casual style. Our pique knit golf t-shirt is a comfortable, lightweight way to play 18-holes and beat the heat. Features, stylish white pearl buttons, yet it feels like wearing your favorite t-shirt. Dress it up or down. Throw a blazer over lat. List Price: $ 20.00 Price: $ 20.00 More Prostate Cancer Apparel Products -
Prostate Cancer Awareness Ribbon Coffee Mug
15 May 2012 | 4:53 pmProstate Cancer Awareness Ribbon Coffee Mug 11 Ounce Ceramic Coffee Mug Dishwasher and Microwave Safe Flag will not fade or discolor Makes a Great Gift or Present High Quality with Lasting Durability – Made in the USA The Prostate Cancer Ribbon proudly displayed on an 11 ounce coffee mug. There is no better way to achieve awareness or remembrance for the meaning of the Prostate Cancer Ribbon than to display it on your coffee mug for everyone to see. The coffee mug is 11 ounces, it is dishwasher safe as well as microwave safe. The colors will not fade or run. Start gaining awareness… -
Men’s Health Prostate cancer Organic Men’s Fitted T-Shirt by CafePress
13 May 2012 | 4:56 pmMen’s Health Prostate cancer Organic Men’s Fitted T-Shirt by CafePress Lightweight for summer comfort or winter layering, our Men’s Organic T-shirt is one of our most popular fine tees. It’s what to wear when you care about having 100% organically-grown cotton next to your skin. The next best thing to nothing, naturally. List Price: $ 32.50 Price: $ 32.50 Related Prostate Cancer Shirt Products -
Prostate Cancer (Understanding Disease: Infectious Diseases & Oncology)
13 May 2012 | 7:09 amGet the facts on Prostate Cancer with this 100%-accurate animated video. Part of Focus Apps’ Understanding Disease: Infectious Diseases & Oncology series, the Prostate Cancer app explores the anatomy of the prostate gland. Prostate cancer is most often referred to as adenocarcinoma or glandular carcinoma. It arises in the peripheral zone from the semen-secreting cells of the prostate gland, a part of the male reproductive system. Understand symptoms, causes, risk factors, staging and prognosis, diagnostic methods, evaluation, treatment options, and recent advances related to…
-
Latest articles from Renal and Urology News Prostate Cancer
-
Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD
14 May 2012 | 11:00 pmSeveral new drugs have become available for treating advanced prostate cancer in the past year and a half. E. David Crawford, MD, head of urologic oncology at University of Colorado (UC) Hospital and an investigator at the UC Cancer Center, both in Aurora, and UC colleague Thomas W. Flaig, MD, recently published a review of these agents. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used. -
Prostate Cancer Outcome Not Tied to Complementary Medicine
7 May 2012 | 8:41 amAlthough widely used, complementary and alternative medicine (CAM) does not impact patient satisfaction with treatment or patient-reported outcomes after treatment for localized prostate cancer. -
Vitamin D May Help Prostate Cancer Patients
5 May 2012 | 7:00 amSmall study shows benefit, but some experts urge caution. -
Selected Prostate Cancer Patients May Benefit from HIFU
4 May 2012 | 5:00 amHigh intensity focused ultrasound (HIFU) may provide an alternative to traditional treatment for localized prostate cancer. British researchers report this use of ultrasound may be high beneficial in a select group of prostate cancer patients. -
Prostate Imaging System Receives FDA Approval
2 May 2012 | 8:09 amThe device may improve clinicians' ability to diagnose prostate cancer.
-
THE "NEW" PROSTATE CANCER INFOLINK
-
Abiraterone in the UK: rumors are rife …
15 May 2012 | 10:29 amAccording to recent articles in the media, the National Institute for Clinical Excellence (NICE) will shortly issue a recommendation that abiraterone is covered for routine use in the UK among men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC). If one believes the media reports (see The Daily Mail yesterday and The Daily Telegraph today), one [...] -
Wanna learn about being a consumer/patient reviewer for the DoD PCRP?
14 May 2012 | 6:28 pmOn Wednesday this week, you can join an hour-long webcast at which Dr. Carolyn Best and a colleague from the Department of Defense Prostate Cancer Research Program (DoD PCRP) will explain what is involved and how to apply. Sign yourself up right NOW! The DoD PCRP is the single largest government-funded research program that is [...] -
DNA methylation and the aggressiveness of prostate cancer
14 May 2012 | 6:08 pmAccording to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.” The relevant research paper has — supposedly – just been published [...] -
PBRT vs. IMRT — are we about to get the definitive trial?
14 May 2012 | 8:04 amAccording to an article in the Boston Globe this morning, we are (supposedly and finally) going to get the study needed to try to demonstrate whether there is a real clinical benefit to proton beam radiation therapy as compared to modern, intensity-modulated radiation therapy in men with localized prostate cancer! The study is to be [...] -
Expert video-discussion on evolution in the management of late stage prostate cancer
12 May 2012 | 6:11 amHere is a link to a recent 20-minute video-discussion on the Medscape web site between an number of European experts on evolutions in the management of castration-resistant (and earlier forms of) prostate cancer. (You do need to sign up to be able to see material on the Medscape web site, but you can opt out [...]
-
About.com Prostate Cancer: What's Hot Now
-
Stage 3 Prostate Cancer
16 May 2012 | 6:10 amHow advanced is stage 3 prostate cancer? How much has prostate cancer spread if it is stage 3? -
Alkaline Phosphatase
16 May 2012 | 6:10 amAlkaline phosphatase is an enzyme found in the blood that can signal that prostate cancer has spread to the bones. The test for alkaline phosphatase is a common and important aspect of the monitoring of prostate cancer. -
Prostate Cancer Chemotherapy
16 May 2012 | 6:10 amChemotherapy is not commonly used to treat prostate cancer. However, there are two specific sets of circumstances where chemotherapy is typically used. It is important to know the basics about this important form of treatment. -
What Is Prostate Cancer?
16 May 2012 | 6:10 amWhat is prostate cancer: The three key questions that anyone interested in this disease must have answered. What is the prostate? What is cancer? What is prostate cancer? -
PET Scan for Prostate Cancer
16 May 2012 | 6:10 amThe PET scan for prostate cancer is an often misunderstood test which is sometimes used to determine the extent of spread of prostate cancer. Learn all about the PET scan for prostate cancer and why prostate cancer is different from any other type of cancer when it comes to PET.
-
About.com: Prostate Cancer
-
Robot-Assisted Surgery
16 May 2012 | 7:09 amRobot-assisted prostate surgery is a relatively new option for treating prostate cancer. This surgery is of great interest to men with prostate cancer as well as the general public, but there are plenty of misconceptions about it. Learn what this procedure really entails here. -
Important Questions About Radiation Therapy
16 May 2012 | 7:09 amRadiation therapy is a widely used treatment for prostate cancer. Radiation therapy can be administered from outside the body (external beam radiation therapy) or from inside the body (brachytherapy). What are the important questions about radiation therapy? -
High PSA Causes
16 May 2012 | 7:09 amWhat are some other causes of an elevated PSA? Thousands of men each year are told that they have a high PSA level after undergoing a routine screening test. The most important and most concerning cause of an elevated PSA is prostate cancer. However, prostate cancer is only one of many potential causes of an elevated PSA. -
Uncommon Symptoms List
16 May 2012 | 7:09 amUrinary problems are the most common initial symptoms of prostate cancer, however, there a number of uncommon symptoms that you should be aware of as well. -
Prostate Infection
16 May 2012 | 7:09 amProstate infections can cause a number of severe symptoms, can lead to dangerous complications, and can mimic the symptoms of more serious conditions such as prostate cancer. Learn all about prostate infections here.
-
Malecare's Advanced Prostate Cancer
-
Download the Updated Advanced Prostate Cancer Book
10 May 2012 | 4:43 pmMalecare’s Advanced Prostate Cancer Book has just had a major update from its first edition. This updated edition can be downloaded for free from the Malecare web page at www.malecare.org. When you get to the page click the box in the upper left of the page that says “ADVANCED PROSTATE CANCER.” Then go to the section that says Advanced Prostate Cancer and fill in your name and email address so we can contact you when there are additional updates. The Advanced Prostate Cancer Book is written for both the newly diagnosed who do not have any understanding of the disease to the… -
GTx Receives clearance for New Capesaris Trials
8 May 2012 | 8:17 pmGTx Inc. announced that FDA regulators will allow it to restart the clinical trials of its investigational prostate cancer drug Capesaris for men with castrate resistant advanced prostate cancer. They anticipate that the trials of Capesaris will begin during the third quarter of 2012. The trial is designed to evaluate Capesaris as a secondary treatment for advanced prostate cancer that no longer responds to hormone treatment, a condition known as being castrate resistant. The trial protocol will test three different doses of Capesaris on 75 men. In February the he FDA ordered GTx to stop the… -
Why Are Gays Excluded From Medical Research Studies?
5 May 2012 | 8:53 pmFor a reason that I can not figure out there are a small but still significant portion of medical studies that automatically exclude gays from participating without an apparent scientific reason. These studies usually have requirements that the subject be in a “reciprocal relationship with a person of the opposite sex.” Sometimes the exclusion of gays is appropriate, for example if the study were looking at how HIV spreads during male-female sex. In this example the researchers would only want heterosexual subjects. But in most studies that exclude gays from the subject pool there is… -
What Is The Actual Survival Advantage for Men Who Take Provenge? It’s Longer Than We Thought!
3 May 2012 | 7:55 pmUnderstanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since is introduction has attracted nothing but controversy. The first rumblings go all the way back to its initial FDA hearing and just continues all the way to today. I cannot think of many drugs or treatments that can boast of such a rocky history. When… -
Zytiga in High Doses and Zytiga Combined with MDV3100 Increase the Length of Response Time In Men with Advanced Prostate Cancer
1 May 2012 | 6:22 pmAccording to recent trials led by The Institute of Cancer Research (ICR) (UK) and The Royal Marsden (UK) combining Zytiga (abiraterone acetate) with the yet FDA unapproved investigational drug MDV3100 could increase the number of men, with advanced prostate cancer, who respond to treatment as well as the length of time they benefit. A new study published today in Cancer Research has identified a reason why men with metastatic prostate cancer ultimately develop resistance to Zytiga. In a laboratory study, Dr Gerhardt Attard and colleagues found that the steroids that are given in combination…
-
Prostate Cancer Advocacy and Action
-
why don’t we care?
10 May 2012 | 7:12 pmJust reflecting on an incident last year. I was out for a jog in my neighborhood, I saw a young family out for a walk… always a wonderful thing to see. The young daughter got something in her eye and began to cry. Both parents immediately rushed to her, letting go of the baby stroller the mother was pushing. As they huddled around their daughter – the baby stroller slowly gained momentum down a hill towards an intersection. My own instinct caused me to pick up pace to a panicked run as I crossed the street to keep the carriage from rolling into the road… with no idea of its… -
Ignorance trumps many dimensions of social justice
9 May 2012 | 7:12 pmWhat happened yesterday in NC (passing of NC Amendment 1) is shameful beyond reason. If you claim to be an advocate for men’s health and you do not advocate for veterans or if you support anti LGBT legislation you are NOT an advocate for men’s health – period. -
Mayan Prophecy
4 May 2012 | 4:47 pmI’ve been thinking lately about the Mayan Prophecy (the world ending on 12/21/12). Apparently a lot of people believe that this end of days might actually be a global re-alignment in thought… whereas we have a whole world that is dominated by patriarchal masculine attitudes and behaviors, even in women, there might be a re-introduction of the feminine divine… where our collective thoughts are more balanced towards nurturing, compassion, and respect vs. well… domineering self-interested BS and the unhealthy variety of competitive attitudes that are born and fostered… -
Ryan O’Neal and Warren Buffet
18 Apr 2012 | 6:18 pmTwo well-known celebrities were diagnosed with cancer this week – and each case illustrates the confusion that is indicative of the experience of cancer diagnosis in our broken medical system. Ryan O’neal announced his diagnosis last Friday (4/13) stating that he has stage 4 prostate cancer, but has been given a “positive” prognosis because it was caught early. Stage 4 PCa is never a positive prognosis, and in all likelihood it was not caught early… if it was caught early that is one seriously aggressive cancer that is very likely well beyond hope for “cure.”… -
Fred Gersh Died Today
5 Apr 2012 | 2:09 pmFred Gersh died earlier this morning, from the Prostate Cancer that he had been fighting for many years. Fred was a friend and ally to Malecare. He spent much of the last decade of his life as a prostate cancer advocate. I met Fred during one of the many conferences we both attended. One day, several years ago, he took my arm and asked me, “what is it about gay men…why does Malecare exit?” That was the start of many conversations about LGBT life, history, sex and love and prostate cancer. Fred was a genuine learner, and, during the last year or so, I witnessed him as a teacher,…
-
prostate-report.org
-
Prostate drug abiraterone ’set for NHS use’
16 May 2012 | 1:33 pmA drug for advanced prostate cancer is likely to be approved for NHS use in England and Wales after the medical watchdog reversed an earlier decision. Abiraterone, initially rejected by NICE for not being cost effective, costs about £3,000 a month and can extend life by more than three months. The decision prompted an angry response from patients and cancer charities. Final approval will be made in June after the manufacturer offered the oral tablet at an undisclosed lower price. -
New tests to detect prostate cancer early
15 May 2012 | 3:10 pmProstate-specific antigen (PSA) testing is one way to find prostate tumors early, but PSA testing can miss some cancers or produce a false-positive result. Meanwhile, researchers at the University of Michigan believe a new urine test is more accurate. The urine test works by identifying gene fusions that occur when pieces of two chromosomes stick together. These fusions are common in prostate cancer. The urine test identified 80 percent of patients with it. -
Biomarkers for prostate cancer detection discovered
14 May 2012 | 1:06 pmA new Mayo Clinic study has found alterations to the “on-off” switches of genes occur early in the development of prostate cancer and could be used as biomarkers - known as DNA methylation profiles - to detect the disease months or even years earlier than current approaches. These biomarkers also can predict if the cancer is going to recur and if that recurrence will remain localized to the prostate or, instead, spread to other organs. The team leades says the PSA test detects any prostate abnormality, whether inflammation, cancer, infection or enlargement, while the DNA… -
National Institute for Clinical Excellence rejects “routine” use of cabazitaxel in UK
13 May 2012 | 2:41 pmA media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, says the institute’s advisory board will not recommend “routine” use of cabazitaxel for the treatment of metastasic, castration-resistant prostate cancer. It is clear from the media release that NICE decided that the price for treatment with cabazitaxel (also known as Jevtana) did not, in its opinion, justify the potential benefits when the risk of complications and side effects of treatment were taken into account. However, NICE will recommend use of the drug in ongoing or future clinical… -
Updated version of book on advanced prostate cancer
12 May 2012 | 5:51 amMalecare has just issued an updated version of its free book on recurrent and advanced prostate cancer. Many people have gained great benefit from the first edition of this book, and we are sure that the new version is equally useful. However, you do have to “sign up” to be able to download the new edition, which will clearly mean that readers start to receive a regular stream of e-mails about related Malecare services. If interested you may sign up here
-
Prostate Cancer Blog for Wives and Partners
-
XGEVA® (denosumab) Does Not Receive FDA Approval
3 May 2012 | 8:22 pmThe FDA has not approved the use of denosumab to treat men with castration-resistant prostate cancer at high risk of developing bone metastases, according to an Amgen press release. The FDA determined that the effect on bone metastases-free survival was of insufficient magnitude to outweigh the risks (including osteonecrosis of the jaw) of denosumab in the intended population, and requested data from adequate and well-controlled trials demonstrating a favorable risk-benefit profile for denosumab. May 3, 2012. -
Small High Intensity Focused Ultrasound Study Shows Promise
17 Apr 2012 | 5:18 pmAlthough high intensity focused ultrasound (HIFU) is not approved for use in the United States, a small UK study by Ahmed et al, is reporting favorable results in the early online version of The Lancet Oncology. With HIFU, small lumps of cancerous prostate tissue are removed, making it somewhat similar to lumpectomy for breast cancer. Then soundwaves cause targeted tissue to heat up, which kills the cancer cells. Proponents claim that HIFU is extremely accurate, effective, and has fewer side effects than conventional treatments, such as radical prostatectomy. In this study of 42 men, 12… -
Study: Antifungal Treatment for Prostate Cancer
12 Apr 2012 | 12:17 pmAntifungal treatment is sometimes used in men with castration-resistant prostate cancer (CRPC). In a recent study by Antonarakis et al, 46 men with CRPC either received daily 200 mg or 600 mg of the antifungal drug itraconazole (Sporanox is the brand name). Results of the study have not yet been published, but were presented at the American Association for Cancer Research annual meeting. MedPage Today reported that men in the high-dose itraconazole group had a progression-free survival (PFS) of 48.4% at 24 weeks versus 11.8% for the men in the 200-mg group. The median PFS was 17 weeks for the… -
Study: Brachytherapy and Men with Gleason 7 Prostate Cancer
29 Mar 2012 | 11:00 amResearchers in British Columbia who compared the records of 1,500 men with prostate cancer (439 men had Gleason 7 disease; 362 men had Gleason 3+4 and 77 men had 4+3 disease) have determined that treatment with I-125 brachytherapy seeds with 6 months of hormone treatment demonstrated excellent biochemical no evidence of disease (using the Phoenix definition of biochemical recurrence, which is nadir PSA + 2.0 ng/mL following brachytherapy) in men with Gleason 7 disease after 5 years. They also found no difference in results between men with Gleason 3+4 or 4+3 disease. These men received I-125… -
Prostate Cancer Statistics for 2012
20 Mar 2012 | 2:29 pmBefore you read these prostate cancer statistics, remember that every man is different and every case of prostate cancer is different.
-
Healthy Living News from Prostate.net
-
Ashwagandha Herb Can Reverse Memory Loss
30 Apr 2012 | 7:26 pmAlthough the work is preliminary, researchers at the National Brain Research Centre (NBRC) say they have shown that the herb ashwagandha may reverse memory loss in Alzheimer’s disease. Their findings were made in mice modified to have Alzheimer’s, a commonly used way to study the disease. Alzheimer’s disease is a progressive brain disease and the most common type of dementia. One characteristic of the disease is the accumulation of protein deposits (beta amyloid) as plaque in the brain, and much of the prevention and treatment research has focused on ways to eliminate this plaque. NBRC… -
Prostate Cancer Risk Higher in Men with Breast Cancer Gene
23 Apr 2012 | 7:01 pmResults of a new study support what researchers have known for some time: there is a connection between breast cancer and prostate cancer—at least when it comes to certain genes. The new study reports that men who have the mutated breast cancer gene BRCA1 are nearly four times more likely to develop prostate cancer than men without the gene. The BRCA1 (breast cancer 1, early onset) gene is a tumor suppressor gene, and it produces a protein that helps prevent cells from growing and dividing uncontrollably, as occurs in cancer. BRCA1 genes also provide instructions for making a protein… -
Protein Discovery Could Lead to New Cancer Treatment
23 Apr 2012 | 5:39 pmScientists at Lund University are on a quest to resolve a classic “if/then” situation involving a protein discovery that could lead to new cancer treatment. Basically, if they can block a protein called gamma-tubulin, then targeted cancer cells should die while healthy cells survive. One major problem with cancer treatment is that most chemotherapy drugs and radiation therapy not only have an effect on cancerous cells, but also damage healthy cells. This cell damage results in side effects and complications that can seriously impact a patient’s quality of life. The Swedish… -
Longevity and Healthy Life Years, a European Study
23 Apr 2012 | 5:38 pmLongevity is how long you live, but how long can you expect to live without disability? The measure of the latter is known as healthy life years, and according to figures released at the European Joint Action on Healthy Life Years, Swedish men had the highest healthy life years of European men in 2010. As the numbers of older adults grow ever larger, there is an accompanying growing interest and concern for issues that impact an aging population. One of the most pressing concerns expressed by aging adults is being disabled or incapacitated so they are not able to enjoy a good quality of life… -
To Boost Your Creative Juices, Try Meditation
23 Apr 2012 | 5:36 pmIf you have been looking for a way to boost your creative juices, you might want to try meditation. Researchers at Leiden University have published a report in Frontiers in Cognition noting the benefits of certain types of meditation in promoting creativity. For many years, both conventional and integrative physicians have been touting the stress reduction and relaxation benefits of meditation, and scores of studies have supported these claims. Meditation has demonstrated health advantages in cancer patients, individuals with asthma, people experiencing emotional distress, and those…


